Alzheimer’s disease Diagnosis and Plasma phospho-tau217-the ADAPT study

October 15, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-10-15 Abstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. Dr Ashvini Keshavan will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. She will then proceed with describing the plan for ADAPT, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study she aims to find out whether plasma p-tau217 helps to diagnose AD more quickly, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways, and we will obtain evidence for its cost effectiveness and acceptability to patients. Bio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre, UCL Queen Square Institute of Neurology. A graduate of Trinity College, Cambridge, she completed postgraduate neurology training in London, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts, aiming toward future application in more real-world settings, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study. This webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Cyber Security Attack Impacts NHS Blood and Transplant

The recent cyber attack on Synnovis has made front-page news over the last few days due to its significant impact on pathology services at London hospitals and the subsequent increased requests for blood donors. The Future Blood Testing Network Plus has consulted researchers, Prof Carsten Maple and Dr Gregory Epiphaniou, from  the Secure Cyber Systems Research Group at WMG, University of Warwick, to gain insight into why this attack has severely affected pathology services.

A recent cyber attack has caused significant challenges for NHS Blood and Transplant leading to the organisation issuing an urgent appeal for blood donations. 

It is becoming commonplace to read or hear about a new cyber attack in the public or professional media. The UK has seen a sharp rise in severe cyber attacks, particularly those aimed at extorting money from the victim – ransomware attacks. According to the National Cyber Security Centre (NCSC), the number of ransomware attacks surged by over 27% in the past year. The NCSC received 2,005 incident reports in 2023, a 64% increase from the previous year, with 371 of these being severe enough to involve their Incident Management team (NCSC Annual Report, 2023).

Ransomware attacks have impacted a broad spectrum of sectors, from healthcare to cultural institutions such as the British Library attack in October last year.

The rise in ransomware is fuelled by a criminal ecosystem where cybercrime services can be easily procured. This allows attackers to execute ransomware attacks effectively. These criminals typically demand payments in cryptocurrencies including Bitcoin, which are difficult to trace. Even if the ransom is paid, victims may not regain access to all their files (Joint Committee on National Security Strategy, 2023).

The attack early this week on Synnovis, a pathology service provider for major London hospitals, disrupted the ability to match patient blood types. This led to an urgent appeal for O-type blood donors. O Positive blood can be given to anyone with a positive blood type, benefiting three-quarters of the population, while O Negative, known as the universal blood type, can be given to any patient (BBC News, 2024a).

The suspected perpetrators of the attack are the Qilin ransomware cyber gang, a Russian group recognised for operating a ransomware-as-a-service model over the last two years. In this instance, the attackers likely accessed Synnovis’ systems by sending phishing emails. Then, they will then have used IAX Active Directory security to increase their privilege level and propagate throughout the network. To coerce victims into paying the ransom, the Qilin gang uses double extortion, encrypting data and exfiltrating private information. The first extortion concerns requiring a payment in exchange for the decryption keys so that the victim can recover information that is encrypted, and the second requires payment to prevent release of the private information.  This latest incident is reflective of a growing pattern of attacks on the healthcare industry, with similar attacks affecting SYNLAB Italia in April 2024 and the NHS Dumfries & Galloway in March 2024.

The NHS has announced that recovery from the attack could take months, and given recent attacks that is likely to be the minimum disruption.  The impact of cyber attacks can be profound and long-lasting. The cyber attack on the British Library led to a major technology outage, causing substantial damage. This has required the installation of a new computing infrastructure, and despite efforts to restore services, disruptions persist. In November, the attackers released some of the library’s data onto the dark web, including personal user information (British Library, 2024). It is unknown which information has been captured in the Synnovis breach, but it is likely that at least some of that will be donor personal information and will be released in some way – the attackers wanting to show they will make good on their threats as a message to future victims. It is likely that as with the British Library, Synnovis and the NHS will work with NCSC to understand and recover from the attack. Despite the escalating threat, less than half of organisations have a formal ransomware plan – indeed it has recently been reported that 8% of victims have resorted to paying ransom demands (Thales, 2024).

The increase in cyber attacks underscores the urgent need for robust cybersecurity measures. Organisations need to develop comprehensive plans to address ransomware threats and invest in resilient defenses. Continuous research and investment in cybersecurity are essential to protect critical national infrastructure, maintain public trust, and ensure national security. Addressing these challenges head-on is crucial for the UK’s resilience against the evolving cyber threat landscape (Craig, 2018; Royal Society, 2022).

Authors

Prof Carsten Maple is Director of the NCSC-EPSRC Academic Centre of Excellence in Cyber Security Research and Professor of Cyber Systems Engineering at the University of Warwick. He is also a co-investigator of the PETRAS National Centre of Excellence for IoT Systems Cybersecurity, is the Research Innovation Director at EDGE-AI, the National Edge Artificial Intelligence Hub, and is a Fellow of the Alan Turing Institute.

Dr. Gregory Epiphaniou is an Associate Professor of Security Engineering at the University of Warwick, focusing on bid support, applied research, and publications. His research includes threat source characterisation and wireless communications, mainly on crypto-key generation through V-V channels. He has led and contributed to research projects worth over £20M, funded by EPSRC, IUK, and local authorities. He holds industry certifications in Information Security and has collaborated with the UK MoD. He is a subject matter expert at the Chartered Institute for Securities and Investments, a technical committee member for scientific conferences, and acted as a key member in forming the UK Cybersecurity Council WS5.

References

BBC News, 2024a. O-type blood donors needed after London cyber-attack. [online] Available at: https://www.bbc.co.uk/news/articles/c2eeg9gygyno.

British Library, 2024. British Library cyber incident review. [online] Available at: https://www.bl.uk/home/british-library-cyber-incident-review-8-march-2024.pdf.

Craig, A., 2018. Effective cyber security research can support the resilience of our digital and physical infrastructures.

Joint Committee on National Security Strategy, 2023. A hostage to fortune: ransomware and UK national security. [online] Available at: https://publications.parliament.uk/pa/jt5804/jtselect/jtnatsec/194/report.html.

NCSC Annual Review, 2023. https://www.ncsc.gov.uk/collection/annual-review-2023

Royal Society, 2022. Continuous investment in cybersecurity to counter evolving risks.

Thales, 2024. Thales data threat report reveals rise in ransomware attacks, as compliance failings leave businesses vulnerable to breaches. [online] Available at: https://www.thalesgroup.com/en/worldwide/security/press_release/2024-thales-data-threat-report-reveals-rise-ransomware-attacks.

Photonic Biosensing of Alzheimer’s Disease Biomarkers

July 5, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-07-05 Abstract: A major issue facing the diagnosis of neurodegenerative disease is the availability of an accessible, scalable, and highly sensitive technology. Compelling evidence now suggests that the abundance of blood-based dementia biomarkers, including ß-amyloid (Aß) and tau, and their ratios, change considerably before clinical symptoms arise. Assessing these parameters via a straightforward blood test could facilitate early-stage diagnosis, recruitment of patients into clinical trials, and open a platform for at-home treatment monitoring. Current technologies for biomarker analysis are resource-intensive, rely on cerebrospinal fluid extraction, and are not widely adopted. Here, we demonstrate the detection of blood-based biomarkers using a next-generation, label-free photonic biosensor based on the principle of chirped guided mode resonance (GMR) spectroscopy. Our handheld GMR device is a low-cost optical biosensor suitable for the real-time, sensitive and parallel detection of dementia biomarkers. The technology utilizes wavelength scale grating structures to excite a standing wave that is sensitive to refractive index changes on the sensor surface. When target biomarkers bind to antibodies on the sensor surface, a refractive index change gives rise to a detectable shift in resonance wavelength. The chirped element of the GMR translates spectral information into spatial position, allowing biomarker binding to be detected by imaging the spatial position of the optical resonance on a simple camera detector. Our label-free technology outperforms competing modalities including surface plasmon approaches, has demonstrable sensitivity to pg/mL concentrations of low molecular weight protein biomarkers, offers a wide dynamic range, is mechanically and thermally stable, enables the real-time detection of at least eight biomarkers in parallel, and corrects for non-specific binding. By applying our biosensing approach to the detection of dementia biomarkers, we have demonstrated the real-time and quantitative detection of Aß in laboratory analytes, paving the way for further developments towards a blood test technology to support disease diagnosis, at-home treatment monitoring, and the democratization of testing. Bio: Dr Steven Quinn obtained an MPhys in Physics from the University of St. Andrews (2009) and an MSc in Radiation, Oncology and Biology from the University of Oxford (2010). After his PhD (St Andrews, 2013) and a postdoctoral position at the University of Glasgow (2013-2016), he took up a Lindemann Trust Fellowship at the Massachusetts Institute of Technology (2016-2017). In 2017, he was appointed to a Lectureship at the University of York and was awarded an Alzheimer’s Research UK Fellowship in 2019. Steven is now a Senior Lecturer, and his group uses a variety of analytical, biosensing and single-molecule techniques to detect and interrogate the structure and dynamics of biomolecules implicated in dementia. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Blood testing miniaturisation – opportunities, trends and challenges. Dr Al Edwards (University of Southampton)

May 17, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-05-17 Abstract: Although the need for better diagnostics, especially point-of-care testing, is clear, the uptake of novel technology lags a long way behind demonstration and research papers. Using several case studies from my own research, alongside insight from current state-of-the art notably in diagnostics for microbiology and infection, I will outline the technological basis for bioassay miniaturisation (i.e. tiny blood tests) and discuss the diagnostics innovation pathway. Examples will include a review of >10 years developing microfluidic quantitative multiplex immunoassays that can measure multiple biomarkers in blood, as well as our latest developments in measuring platelet cell function directly in blood. Bio: With a background in fundamental immunology combined with expertise in biochemical engineering, Al Edwards is an interdisciplinary researcher focussed on solving current and future healthcare challenges using an engineering science approach that combines a range of fields from biology, biochemistry, chemistry and physics. He works at the interface between academic technology discovery and industrial development and have experience of both fundamental research and the commercialisation of new technology. The two main challenges he currently work on are the development of affordable microfluidic technology for clinical diagnostics and microbiology, and the engineering science of complex biologic therapeutics such as vaccines. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Rapid Blood Tests: The Two-Year Manifesto. Dr Martin Peacock (Zimmer and Peacock Ltd)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-04-17

Abstract: Zimmer and Peacock has worked on the development and manufacture of a platform intended to translate academic blood testing assays from the lab into the clinical setting, and onto the market. At ZP, for research to be impactful and sustainable, it does need to be presented in a form factor so that it can be easily used by clinicians and patients. In this webinar and live streaming demo, ZP will show how a scientific paper can easily become a clinical product. The policy at ZP is to translate science into regulatory approved products in 2 years or less.

Bio: Martin Peacock is an industrial bioelectrochemist with over twenty years of biosensor experience, having had industrial roles from Abbott Diabetes to GSK, and solving technical challenges from continuous glucose monitoring to RNA analysis. He is a Director at Zimmer and Peacock Ltd, a company that sees sensors as a critical part of various social and commercial revolutions, such as the Internet of Things (IoT), Sensor Web, and the Invitro Diagnostics Market (IVD). With over eight years of experience in this role, he lead a team of talented scientists and engineers who partner with academia and industry to develop and manufacture innovative sensors and medical diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Routine cellular diagnostics: A platelet perspective? Dr Chris Jones (University of Reading)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-03-26

Abstract: The idea of conducting tests for an infectious disease on the kitchen table would have seemed unimaginable only three years ago; now, it is a routine part of life in the UK. Similarly, measuring health markers such as heart rate or blood pressure used to involve a trip to your GP’s surgery; now, they are measured by your watch.  Routine testing of cellular function may be the next step, supplying data on cellular changes that occur before the presentation of symptoms or rapidly assessing the efficacy of therapies.  Platelets play a vital role in chronic and acute cardiovascular disease but also have roles in immunity, inflammation, cancer metastasis, Alzheimer’s disease and infections, such as dengue, HIV-1, malaria, and COVID-19.  In addition, they are easily obtained from subjects or patients, making them valuable biomarkers for changes in blood vessels associated with disease, ageing or therapy. This seminar will introduce the utility of platelets as a cellular biomarker and the progress we have made in designing tests that capture the function of these cells, both in the lab and at point-of-care.

Bio: Chris Jones is an Associate Professor of the Thrombosis and Heamostasis in the school of Biological Sciences at the University of Reading. Over two decades, he has designed and employed innovative platelet function assays to provide novel insights into platelet dysfunction. His lab has also developed analysis software for platelet activation assays and employed microfluidics, open hardware and smartphone technology to develop low-cost point-of-care platelet function assays. These new technologies have led to HaemAnalytica, a soon-to-be established spinout, which will provide complete platelet function analysis for clinical trials and diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

The Future of Healthcare: Remote Blood Testing, Monitoring & AI

Registration Link: https://www.store.reading.ac.uk/conferences-and-events/henley-business-school/workshops/the-future-of-healthcare-remote-blood-testing-monitoring-ai

Formal Event Flyer: https://futurebloodtesting.org/fbtn2023/eventflyer

Description:

At the Future Blood Testing Network Plus, we are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. This two day workshop will feature speakers to discuss the future of healthcare, remote blood testing, monitoring and artificial intelligence (AI).

This event will take place at Leonardo Hotel Southampton (Formerly Jurys Inn). Both days will include lunch and coffee breaks, with day 1 also including a drinks reception with dinner.

NB: Due to venue policies on final numbers we cannot guarantee that we can cater to all dietary requirements after the 12th October. 

Event Costs

  • £30 – Physical Day Attendance (Includes lunch on both days, and dinner and drinks on day 1)
  • £50 – Accommodation (per night – Bed and Breakfast available on the 6th and 7th November)

Draft Agenda

Day 1 – 7th November

  • 10:00-10:30: Coffee & Registration
  • 10:30-12:00: Session 1: Landscape of Future Blood Testing – Session Chair: Dr Samantha Pearman-Kanza (University of Southampton)
    • 10:30-11:00: Future Blood Testing Network+ Overview and RecapProfessor Weizi (Vicky) Li (University of Reading)
    • 11:00-11:30: Remote Testing & AI – What’s Coming NextMr Frank Khan Sullivan (Enhanced Fertility)
    • 11:30-12:00: Landscape of Future blood testing in healthcare practice – Professor Dimitris Grammatopoulos (University of Warwick)
  • 12:00-13:00: Lunch & Photo session
  • 13:00-15:00: Session 2: Network Funded Projects  – Session Chair: Prof Weizi (Vicky) Li (University of Reading)
    • 13:00-13:30: Multi-modal deep learning approaches for identification of prognostic and diagnostic biomarkersDr Heba Sailem (Kings College London)
    • 13:30-14:00: FERRIQ: AI-Driven mapping of disease trajectories of patients with genetic iron overload to inform development of clinical decision support systemsDr Fayyaz Minhas & Professor Dimitris Grammatopoulos (University of Warwick)
    • 14:00-14:15: Development of an implantable device for continuous monitoring of blood biomarkersDr Chenyang He (University of Nottingham)
    • 14:15-14:30: Blood microfluidics for point of care diagnosticsProfessor Stavroula Balabani (UCL)
    • 14:30-14:45: Raman spectroscopy for remote blood testing – Dr Donna Arnold (University of Kent)
    • 14:45-15:00: Wearable Otological Measurement of Blood Analytes (WOMBA) – Dr Peter J. Christopher (University of Nottingham)
  • 15:00-15:15: Coffee Break
  • 15:15-17:15: Session 3: Adoption & Design for the Future of Digital Healthcare & Diagnostics: Design, data, NHS adoption and commercialisation
    • 15:15-15:30: Information Design in medical testingProfessor Sue Walker (University of Reading)
    • 15:30-17:15: Round Table (facilitated by Al, Sue, Mamta, Age)
      • Design: Professor Sue Walker (University of Reading)
      • Data: Professor Age Chapman (University of Southampton)
      • NHS adoption: Dr Mamta Bajre (Oxford Academic Health Science Network)
      • Commercialisation: Associate Professor Alexander Edwards (University of Southampton)
  • 17:10-17:30: Wrap Up
  • 17:30-19:00: Drinks Reception & Networking
  • 19:00: Conference Dinner

Day 2 – 8th November

  • 09:30-09:55: Coffee
  • 09:55-10:00: Welcome BackProfessor Weizi (Vicky) Li (University of Reading)
  • 10:00-12:30: Session 4: Future Blood Testing Research – Chair: Dr Mark Elliott (University of Warwick)
    • 10:00-10:30: Translating blood tests from the Academic Lab into the Clinical Setting – a Case StudyDr Martin Peacock (Zimmer and Peacock Ltd)
    • 10:30-11:00: An immune score based on longitudinal blood testingDr Hector Zenil (Oxford Immune Algorithmics)
    • 11:00-11:30: Coffee Break
    • 11:30-12:00: Detection of drugs and biomarkers in healthcare using optical fibre sensorsProfessor Serhiy Korposh (University of Nottingham)
    • 12:00-12:30: Squishing Biology to Advance Healthcare: A Journey from Saliva to Blood
      Dr Robert Barker (University of Kent)
  • 12:30-13:30: Lunch

13-14/09/2022 – Future Blood Testing: Challenges & Opportunities

Eventbrite Link: https://fbtn-workshop-sept2022.eventbrite.co.uk 

Formal Event Flyer: https://futurebloodtesting.org/wp-content/uploads/2022/09/ReadingFlyerFinalVersion.pdf

Description:
At the Future Blood Testing Network Plus, we are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. This two day workshop will feature speakers to discuss the challenges and opportunities associated with this. We will also be launching our second funding call for both our technical landscape report, and for our pilot projects. This event will run as a hybrid event, the physical event will take place at the University of Reading in the Park House Building. Both days will include lunch and coffee breaks, with Day 1 also including a drinks reception with canapés, and dinner. Virtual attendees will be able to join us via Zoom.

NB: Due to venue policies on final numbers we cannot guarantee that we can cater to all dietary requirements after the 30th August. 

Posters & Pitches:
There will be an opportunity to submit a short pitch to present at this 2 day event. Please fill in our Pitch Form to submit a poster or pitch presentation.

  • Pitches will be one minute long with 1-2 slides. Delegates will introduce their expertise and collaborations they are looking for to develop a collaborative innovation project

NB: Pitch Presentations can take place virtually or physically. If you are planning on attending physically to give a pitch, you MUST have registered via our Eventbrite. You need to be registered in order to have your submission accepted. 

The deadline for submissions via this form is the 13th September (however we will email you as soon as we get your submission to tell you if you have been accepted or not).

Electronic copies of pitches should be sent to Dr Samantha Kanza s.kanza@reading.ac.uk by the 13th September. 

Agenda:

Day 1 – 13th September – Park House Building. The main workshop, refreshments, and the conference dinner will take place in the Meadow Suite, and the Drinks Reception will take place in Blandfords.

Time Session/Talk
09:30-10:00 Coffee & Registration
10:00-10:15 Future Blood Testing Network+ Overview
Prof Weizi (Vicky) Li (University of Reading)
Session 1: Chaired by Dr Robert Barker (University of Kent)
10:15-11:00 Transforming the UK’s diagnostics agenda after COVID-19 and grand challenges – Future Blood Testing Landscape report
Prof Dimitris Grammatopoulos (University Hospitals Coventry & Warwickshire, University of Warwick)
11:00-11:45 Measuring platelet function: new strategies for precision medicine to prevent thrombosis
Prof Jon Gibbins (University of Reading)
11:45-12:15 Coffee Break, Networking – There will also be a Group Photo
12:15-13:00 Lab services for a Web 3.0 world: how the next transformation will enable the democratisation of blood testing to have access and control of our own health
Dr Hector Zenil (University of Oxford & Oxford Immune Algorithmics)
13:00-14:00 Lunch
Session 2: Chaired by Prof Jeremy Frey (University of Southampton)
14:00-14:30 Remote blood monitoring for cancer patients- a preliminary landscape analysis
Beth Harvey (University of Reading)
14:30-15:00 Improving triaging from primary care into secondary care using heterogeneous data-driven hybrid machine learning: A real-world case study of decision support system using blood test & GP referral letters
Bing Wang and Prof Weizi (Vicky) Li (University of Reading)
15:00-15:45 Unmet Clinical Needs and Case Studies in Blood Testing
Prof Bryant Lin and Dr. Kevin Chang (Stanford University)
15:45-16:00 Coffee Break & Networking
Session 3: Chaired by Dr Samantha Kanza (University of Reading)
16:00-16:30 Collaborative Innovation Project funding launch
Dr Samantha Kanza (University of Reading)
16:30-17:00 One-minute pitch
Delegates introduce their expertise and collaborations they are looking for to develop a collaborative innovation project
17:00-19:00 Drinks Reception & Networking
19:00-20:00 Dinner & Networking

Day 2 – 14th September – Park House Building. The main workshop, and refreshments will take place in the Meadow Suite.

Time Session/Talk
09:30-10:00 Coffee & Registration
10:00-10:05 Welcome back
Prof Weizi (Vicky) Li (University of Reading)
Session 4: Chaired by Prof Serhiy Korposh (University of Nottingham)
10:05-10:35 Digital Solutions and Remote Monitoring in Real World Clinics
Dr Antoni Chan (Royal Berkshire NHS Foundation Trust)
10:35-11:05 ”Tiny Test Tubes” for affordable microfluidic blood measurements at the point of need
Dr Alexander Edwards (University of Reading)
11:05-11:20 Coffee Break & Networking
Session 5: Chaired by Claire Read (Healthcare Writer)
11:20-13:00 Panel discussion:
– Grand challenges of future blood testing
– Can NHS make use of remote blood monitoring and lessons learned from COVID testing
– Fake it till you make it? How do we achieve the future of blood testing without becoming the next Theranos?
Panel: Prof Neil Anderson, Dr Keith Arundale, Dr Antoni Chan, Dr Alexander Edwards, Prof Dimitris Grammatopoulos, Julie Hart
13:00-14:00 Lunch
Session 6: Chaired by Dr Mark Elliott (University of Warwick)
14:00-14:45 Artificial intelligence for identification of blood cells
Prof Huiyu Zhou (University of Leicester)
14:45-15:15 Precision Health and AI: improving health for everyone
Arjun Panesar (DDM Health)
15:15-15:30 Coffee Break & Networking
Session 7: Chaired by Dr Samantha Kanza (University of Reading)
15:30-16:15 One-minute pitch
Delegates introduce their expertise and collaborations they are looking for to develop a collaborative innovation project. Groups developed from the event present their concept and proposal outline 
16:15-16:30 Closing Remarks
Prof Weizi (Vicky) Li & Dr Samantha Kanza (University of Reading)

 

28/03/2022 – Future Blood Testing Network launches Mini Track at HICSS

The Future Blood Testing Network Team are running a Mini-Track at the HICSS Conference in Hawaii, 3-6th January 2023.

Details of our track on Digitally-Enabled Blood Testing in Healthcare can be found here: https://hicss.hawaii.edu/tracks-56/information-technology-in-healthcare/#digitally-enabled-blood-testing-in-healthcare-minitrack

We invite you to submit papers to our minitrack, the deadline is 15th June. Submission details and author instructions can be found here: https://hicss.hawaii.edu/authors/

Full details can be found here: https://futurebloodtesting.org/hicss-minitrack/

03/02/2021 – Future Blood Testing Network+ Landscape Report Funding Town Meeting

February 3, 2022 @ 3:00 pm 4:30 pm

Eventbrite Link: https://futurebloodtechtownmeeting-030222.eventbrite.co.uk  Description: This is the virtual launch event for the Future Blood Testing Network! The Future Blood Testing Network+ is a new Network funded by EPSRC. We are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. 

Our first funding call will be to fund three projects to produce content for our landscape report that will provide the roadmap of developing new digital health systems to support real-time blood monitoring, self management and timely intervention in community health and care. Each report will include a systematic review of the key literature and involve interviewing key stakeholders to establish the current picture and identify the gaps.

The report will have three main streams:

  • Future blood testing in healthcare practice: For example but not limited to: clinical needs, early adopters, challenges and opportunities, regulations, buy-in, user acceptance, existing and potential use cases for healthcare professionals and hospitals, patients, laboratories etc
  • Remote blood processing and monitoring: For example but not limited to: sensing, imaging, point of care blood testing, portable and affordable , non-invasive, and other promising technologies for detecting blood biomarkers outside clinical settings
  • ICT, Data, Analytics and AI: For example but not limited to: challenges and opportunities in entire data lifecycle from point of testing/monitoring, to linking in with NHS Systems and other healthcare Systems including aspects of ICT infrastructure, data security, trust, ethics, data quality, provenance etc, and the AI technologies and analytics methods required to create the personalised analytics in patient pathways

Register for our town meeting to find out how to apply to this funding call! Please also fill out our expression of interest if you haven’t done so already: https://forms.office.com/r/Y3uCf0CqR7

Agenda:

Time Talk Speaker
15:00-15:05 Welcome Dr Samantha Kanza (Network Coordinator)
15:05-15:15 Network Introduction Dr Weizi Li (Network Director)
15:15-15:30 Introducing the Funding Call Dr Samantha Kanza (Network Coordinator)
15:30-16:25 Panel Q+A  Dr Weizi LiDr Rob Barker, Dr Mark Elliott, Prof Jeremy Frey, Dr Serhiy Korposh, Dr Samantha Kanza
16:25-16:30 Wrap up Dr Weizi Li (Network Director)

Details

Organiser

Online